Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/ Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T- Cell Therapy in the US

被引：0
|
作者：
Epperla, Narendranath [1 ]
Lucero, Melanie [2 ]
Bailey, Tom [3 ]
Mirams, Laura [3 ]
Cheung, Jolenta [3 ]
Amet, Mona [3 ]
Milligan, Gary [3 ]
Keir, Chris [4 ]
Chen, Lei [5 ]
机构：
[1] Ohio State Univ, Columbus, OH USA
[2] ADC Therapeut Amer Inc, New Providence, NJ USA
[3] Adelphi Real World, Macclesfield, Cheshire, England
[4] ADC Therapeut, Murray Hill, NJ USA
[5] ADC Therapeut, New Providence, NJ USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
loncastuximab tesirine; CD19-targeted chimeric antigen receptor T-cell therapy; real-world evidence; treatment sequencing;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-370
引用
收藏
页码：S476 / S476
页数：1
相关论文
共 50 条
  • [21] Chimeric Antigen Receptor T-Cell Therapy Treatment Patterns: A Retrospective Cohort Analysis of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients in the US
    Seyedin, Roxanna
    Snider, Julia Thornton
    Rajagopalan, Krithika
    Wade, Sally W.
    Gergis, Usama
    BLOOD, 2021, 138
  • [22] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
    Saverno, Kimberly
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Gordon, Sarah
    Amoloja, Theresa
    Llorente, Mae
    Epperla, Narendranath
    Nastoupil, Loretta J.
    BLOOD, 2023, 142
  • [23] Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers
    Zelikson, Viktoriya
    Gurumurthi, Ashwath
    Sawalha, Yazeed
    Annunzio, Kaitlin
    Saha, Aditi
    Dong, Ning
    Qualls, David
    Amoozgar, Behzad
    Kahl, Brad
    Baird, John
    Challa, Pavan
    Huntington, Scott F.
    Santos, Jennifer
    Bair, Steven
    Narkhede, Mayur
    Li, Shuning
    Frosch, Zachary
    Ho, Carrie
    Smith, Stephen D.
    Winter, Allison
    Landsburg, Daniel
    Furqan, Fateeha
    Hamadani, Mehdi
    Baird, Katelin
    Romancik, Jason
    Alharthy, Hanan
    Law, Jennie
    Bojanini, Leyla
    Advani, Ranjana
    Hu, Boyu
    Johnson, Patrick Connor
    Grover, Natalie S.
    Merril, Mwanasha
    Crombie, Jennifer L.
    Shafagati, Nazila
    Sterling, Cole
    Nastoupil, Loretta J.
    Epperla, Narendranath
    Ayers, Emily C.
    HAEMATOLOGICA, 2025, 110 (03) : 706 - 714
  • [24] Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report
    Chen, Hsin-Hui
    Kuo, Cheng-Yi
    Ho, Ching-Liang
    Chen, Yeu-Chin
    MEDICINE, 2023, 102 (41) : E35432
  • [25] Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma
    Crombie, Jennifer L.
    Jun, Monika
    Wang, Tongsheng
    Mutebi, Alex
    Wang, Anthony
    Chhibber, Anindit
    Kamalakar, Rajesh
    Ukropec, Jon
    Blaedel, Julie
    Kalsekar, Anupama
    LEUKEMIA & LYMPHOMA, 2024, 65 (11) : 1623 - 1633
  • [26] Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma
    Gatwood, Justin
    Masaquel, Anthony
    Fox, David
    Sheinson, Daniel
    James, Cameron
    Li, Jia
    Hossain, Farah
    Ross, Ryan
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 738 - 745
  • [27] Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma
    Wang, Tao
    Gao, Lei
    Wang, Yujie
    Zhu, Wenjun
    Xu, Lili
    Wang, Yang
    Yue, Wenqin
    Tang, Gusheng
    Chen, Li
    Chen, Jie
    Zhang, Weiping
    Yu, Xuejun
    Feng, Dongge
    Yang, Jianmin
    IMMUNOTHERAPY, 2020, 12 (13) : 997 - 1006
  • [28] DURABLE RESPONSES FOLLOWING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/ REFRACTORY LARGE B-CELL LYMPHOMA AFTER MULTIPLE LINES OF TREATMENT: THE HELLENIC REAL-WORLD EXPERIENCE
    Bampali, Vasiliki
    Dolgyras, Panagiotis
    Matheakakis, Angelos
    Alexandropoulos, Alexandros
    Tsonis, Ioannis
    Gavriilaki, Eleni
    Tzannou, Ifigeneia
    Batsis, Ioannis
    Tzenou, Tatiana
    Mallouri, Despina
    Bouzani, Maria
    Vardi, Anna
    Anagnostopoulos, Achilles
    Gigantes, Stavros
    Sotiropoulos, Damianos
    Karakasis, Dimitrios
    Baltadakis, Ioannis
    Sakellari, Ioanna
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 211 - 211
  • [29] Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
    Iacoboni, Gloria
    Iraola-Truchuelo, Josu
    Martinez-Cibrian, Nuria
    Bailen, Rebeca
    Corral, Lucia Lopez
    Sanchez, Jose M.
    Gonzalez, Ana Carolina Carolina Caballero
    Mussetti, Alberto
    Sancho, Juan-Manuel
    Hernani, Rafael
    Solano, Carlos
    Balari, Anna Sureda
    Briones, Javier
    Garcia-Sancho, Alejandro Martin
    Kwon, Mi
    Reguera, Juan Luis
    Barba, Pere
    BLOOD, 2020, 136
  • [30] Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
    Iacoboni, Gloria
    Villacampa, Guillermo
    Martinez-Cibrian, Nuria
    Bailen, Rebeca
    Lopez Corral, Lucia
    Sanchez, Jose M.
    Guerreiro, Manuel
    Carolina Caballero, Ana
    Mussetti, Alberto
    Sancho, Juan-Manuel
    Hernani, Rafael
    Abrisqueta, Pau
    Solano, Carlos
    Sureda, Anna
    Briones, Javier
    Martin Garcia-Sancho, Alejandro
    Kwon, Mi
    Luis Reguera-Ortega, Juan
    Barba, Pere
    CANCER MEDICINE, 2021, 10 (10): : 3214 - 3223
12345